Literature DB >> 29143274

Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients.

Xiaogang Tao1, Kun Wang2, Jinqian Dong1, Zonggang Hou1, Zhen Wu1, Junting Zhang1, Baiyun Liu3,4,5,6,7.   

Abstract

Secretory meningioma (SM) is a rare histological subtype of the meningioma family. Few reports investigating SM have been published due to its extremely low incidence; thus, the current understanding of this disease is poor. We analyzed the incidence and clinical, radiological, pathological, and prognostic features of SM. Approximately 12,380 intracranial meningiomas were surgically resected at Beijing Tiantan Hospital between April 2008 and January 2017. All pathologically confirmed SM cases were identified. SMs accounted for approximately 1.2% of the intracranial meningiomas (149 of 12,380). The patients with SM had a mean age of 51.0 years and were predominantly female (112 female and 37 male). Radiologically, peritumoral brain edema was observed in 49 (32.9%) patients. Gross total resection was achieved in 115 (77.2%) cases. At the 35-months median follow-up (range 4-109 months), six patients had tumor recurrence, and one patient died from the tumor recurrence. The 5-year progression-free survival rates were 95.9%, and the 5-year overall survival rate was 99.3%. A skull base location and a tumor size ≥ 3.5 cm were significantly associated with poor short-term outcomes, and a skull base location was significantly associated with an increased risk of poor long-term outcomes (P < 0.05). A skull base location (OR 3.797; 95% CI 1.071-13.468; P = 0.039) and tumor size ≥ 3.5 cm (OR 2.616; 95% CI 1.107-6.181; P = 0.028) were independent risk factors for non-gross total resection. A son-skull base location (OR 0.070; 95% CI 0.028-0.177; P = 0.001) was the only independent risk factor that correlated with more severe peritumoral brain edema. SM is a rare subtype of meningiomas with a female predominance and low recurrence. Our results highlight the risk factors for short- and long-term outcomes, which can be useful for selecting treatments and predicting prognosis. Microsurgical treatment of a skull base SM remains a formidable challenge due to a large tumor size and critical neurovascular structure encasement.

Entities:  

Keywords:  Clinical features; Peritumoral brain edema; Prognosis; Secretory meningioma; Skull base

Mesh:

Year:  2017        PMID: 29143274     DOI: 10.1007/s11060-017-2671-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Observations on the formation of psammoma bodies and pseudopsammoma bodies in meningiomas.

Authors:  J KEPES
Journal:  J Neuropathol Exp Neurol       Date:  1961-04       Impact factor: 3.685

2.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

3.  Secretory Meningiomas: Increased Prevalence of Seizures Secondary to Edema Formation in a Rare Histologic Subtype.

Authors:  Malte Mohme; Pedram Emami; Jan Regelsberger; Jakob Matschke; Katrin Lamszus; Manfred Westphal; Sven Oliver Eicker
Journal:  World Neurosurg       Date:  2016-05-27       Impact factor: 2.104

4.  Secretory meningioma. A distinct subtype of meningioma.

Authors:  A Alguacil-Garcia; N M Pettigrew; A A Sima
Journal:  Am J Surg Pathol       Date:  1986-02       Impact factor: 6.394

5.  Secretory meningioma: immunohistochemical findings and evaluation of mast cell infiltration.

Authors:  Wuttipong Tirakotai; Hans-Dieter Mennel; Ilhan Celik; Dieter Hellwig; Helmut Bertalanffy; Thomas Riegel
Journal:  Neurosurg Rev       Date:  2005-07-12       Impact factor: 3.042

Review 6.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

7.  Secretory meningiomas: clinical, radiological and pathological findings in 70 consecutive cases at one institution.

Authors:  Dai-Jun Wang; Qing Xie; Ye Gong; Yin Wang; Hai-Xia Cheng; Ying Mao; Ping Zhong; Feng-Ping Huang; Kang Zheng; Yong-Fei Wang; Wei-Min Bao; Bo-Jie Yang; Hong Chen; Li-Qian Xie; Ming-Zhe Zheng; Hai-Liang Tang; Hong-Da Zhu; Xian-Cheng Chen; Liang-Fu Zhou
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

Review 8.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

9.  Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.

Authors:  David E Reuss; Rosario M Piro; David T W Jones; Matthias Simon; Ralf Ketter; Marcel Kool; Albert Becker; Felix Sahm; Stefan Pusch; Jochen Meyer; Christian Hagenlocher; Leonille Schweizer; David Capper; Phillipp Kickingereder; Jana Mucha; Christian Koelsche; Natalie Jäger; Thomas Santarius; Patrick S Tarpey; Philip J Stephens; P Andrew Futreal; Ruth Wellenreuther; Jürgen Kraus; Doris Lenartz; Christel Herold-Mende; Christian Hartmann; Christian Mawrin; Nathalia Giese; Roland Eils; V Peter Collins; Rainer König; Otmar D Wiestler; Stefan M Pfister; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-02-12       Impact factor: 17.088

Review 10.  Epidemiology of meningiomas.

Authors:  I Baldi; J Engelhardt; C Bonnet; L Bauchet; E Berteaud; A Grüber; H Loiseau
Journal:  Neurochirurgie       Date:  2014-09-22       Impact factor: 1.553

View more
  1 in total

1.  Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype.

Authors:  Leihao Ren; Lingyang Hua; Zhongyuan Bao; Hiroaki Wakimoto; Ye Gong; Jiaojiao Deng; Daijun Wang; Jiawei Chen; Hong Chen; Tareq A Juratli
Journal:  J Neurooncol       Date:  2022-05-25       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.